Special Issue "Marine Compounds and Cancer"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (31 January 2015)
Dr. Friedemann Honecker (Website)
Tumor and Breast Center ZeTuP St. Gallen, Rorschacherstr. 150, CH-9006 St. Gallen, Switzerland
Fax: +41 71 2430 044
Interests: medical oncology; drug resistance; marine anti-cancer compounds; drug development; tumor biology; proteomics
Dr. Sergey A. Dyshlovoy
1 Laboratory of Marine Natural Products Chemistry, G.B. Elyakov Pacific Institute of Bioorganic Chemistry FEB RAS, Prospekt 100-let Vladivostoku 159 (room 312), 690022 Vladivostok, Russia
2 Laboratory of Experimental Oncology, Department of Internal Medicine II and Clinic (Oncology Center), University Medical Center Hamburg-Eppendorf, Martinistr. 52 (N27, room 4.082), 20246 Hamburg, Germany
Fax: +7 423 2314050; +49 40 7410 55896 (Germany)
Interests: bioactive marine natural products; molecular mechanism of anticancer activity; carcinogenesis; drug target identification and validation; proteomics; drug combination studies
In Western countries, cancer is among the most frequent causes of death. Despite striking advances in cancer therapy, especially by the so called “targeted agents”, there is still an urgent need for new drugs in oncology. Hope comes from the marine environment, which is a rich source of natural compounds showing anti-cancer activity. To date, three marine cytotoxic substances, namely cytarabine, trabectidine, and eribulin, have made it into clinical routine. Many more are in all phases of clinical testing, and a plethora of substances has already been examined for in vitro and in vivo activity.
Interestingly, more and more precise research tools allow the dissection of the molecular mode of action of these cytotoxic substances, thereby uncovering the specific drug targets in cancer cells. This development will blur the edges between “targeted” and “untargeted” therapy, and will hopefully lead to a more directed use of cancer medicine (based on a molecular rationale of activity) in the future.
This special issue in Marine Drugs will cover the whole scope from agents with cancer-preventive activity, to novel and previously characterized compounds with anti-cancer activity, both in vitro and in vivo, and the latest status of clinical development from drug trials. In addition, focus will be placed on current shortfalls and possible strategies in the area of marine anti-cancer drug development.
Dr. Friedemann Honecker
Dr. Sergey A. Dyshlovoy
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed Open Access monthly journal published by MDPI.
- marine natural compounds and their derivatives
- marine toxins
- drug discovery
- cancer-preventive activity
- molecular effects
- molecular targets
- xenograft models